ICICI Securities maintains an Add call on Apollo Hospitals Enterprise, raising the target price to Rs 7,500. This revision reflects anticipated faster growth and improved margins in the pharmacy sector. The brokerage has increased revenue, EBITDA, and PAT estimates for FY26 and FY27, valuing the hospital business at 25x FY27E EV/EBITDA.
Tata Sons boardroom battle intensifies but Tata Group stocks remain unbothered. Should you buy?
Tata Sons has rejected Noel Tata’s objections to N Chandrasekaran’s reappointment, saying the board’s decision was valid and made in accordance with the company’s Articles